These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 7670397

  • 1. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia.
    Beaujean F, Bernaudin F, Kuentz M, Lemerle S, Cordonnier C, Le Forestier C, Reinert P, Duedari N, Brandely M, Vernant JP.
    Bone Marrow Transplant; 1995 May; 15(5):691-6. PubMed ID: 7670397
    [Abstract] [Full Text] [Related]

  • 2. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K, Margolin K, Champlin R, Forman S.
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [Abstract] [Full Text] [Related]

  • 3. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS, Tessmer-Tuck J, Pierson BA, Weisdorf D, McGlave P, Blazar BR, Katsanis E, Verfaillie C, Lebkowski J, Radford J, Burns LJ.
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [Abstract] [Full Text] [Related]

  • 4. Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts.
    Rowley SD, Piantadosi S, Marcellus DC, Jones RJ, Davidson NE, Davis JM, Kennedy J, Wiley JM, Wingard JR, Yeager AM.
    Bone Marrow Transplant; 1991 Mar; 7(3):183-91. PubMed ID: 2059755
    [Abstract] [Full Text] [Related]

  • 5. Phenotypic and functional characterization of peripheral blood and bone marrow natural killer cells prior to autologous transplantation.
    Arbour S, Toupin S, Bélanger R, Gyger M, Hallé JP, Perreault C, Roy DC.
    Bone Marrow Transplant; 1996 Mar; 17(3):315-22. PubMed ID: 8704680
    [Abstract] [Full Text] [Related]

  • 6. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 7. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration.
    Klingemann HG, Eaves CJ, Barnett MJ, Eaves AC, Hogge DE, Nantel SH, Reece E, Shepherd JD, Sutherland HJ, Phillips GL.
    Bone Marrow Transplant; 1994 Sep; 14(3):389-96. PubMed ID: 7994260
    [Abstract] [Full Text] [Related]

  • 8. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies.
    Albin N, Douay L, Fouillard L, Laporte JP, Isnard F, Lesage S, Ozsahin H, Bardinet D, Najman A, Gorin NC.
    Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241
    [Abstract] [Full Text] [Related]

  • 9. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M, Couture F, Kovacs M, Saragosa R, McCrae J, Brandwein J, Huebsch L, Beauregard-Zollinger L, Keating A.
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [Abstract] [Full Text] [Related]

  • 10. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
    Kiyoi H, Kojima S, Kato K, Matsuyama T, Kodera Y, Ohno R, Naoe T.
    Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
    [Abstract] [Full Text] [Related]

  • 11. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
    Blaise D, Attal M, Reiffers J, Michallet M, Bellanger C, Pico JL, Stoppa AM, Payen C, Marit G, Bouabdallah R, Sotto JJ, Rossi JF, Brandely M, Hercend T, Maraninchi D.
    Eur Cytokine Netw; 2000 Mar; 11(1):91-8. PubMed ID: 10705305
    [Abstract] [Full Text] [Related]

  • 12. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A.
    Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
    [Abstract] [Full Text] [Related]

  • 13. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM, Fortuna A, Fogli M, Gherlinzoni F, Rosti G, Catani L, Gozzetti A, Miggiano MC, Tura S.
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [Abstract] [Full Text] [Related]

  • 14. Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) administration after autologous bone marrow transplantation for acute myeloblastic leukemia enhances activated killer cell function and may diminish leukemic relapse.
    Richard C, Baro J, Bello-Fernandez C, Hermida G, Calavia J, Olalla I, Alsar MJ, Loyola I, Cuadrado MA, Iriondo A.
    Bone Marrow Transplant; 1995 May; 15(5):721-6. PubMed ID: 7670401
    [Abstract] [Full Text] [Related]

  • 15. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms.
    Long GS, Cramer DV, Harnaha JB, Hiserodt JC.
    Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956
    [Abstract] [Full Text] [Related]

  • 16. Bone marrow-resident memory T cells survive pretransplant chemotherapy and contribute to early immune reconstitution of patients with acute myeloid leukemia given mafosfamide-purged autologous bone marrow transplantation.
    Casorati G, Locatelli F, Pagani S, Garavaglia C, Montini E, Lisini D, Turin I, Rossi F, Dellabona P, Maccario R, Montagna D.
    Exp Hematol; 2005 Feb; 33(2):212-8. PubMed ID: 15676215
    [Abstract] [Full Text] [Related]

  • 17. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
    Massumoto C, Benyunes MC, Sale G, Beauchamp M, York A, Thompson JA, Buckner CD, Fefer A.
    Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
    [Abstract] [Full Text] [Related]

  • 18. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
    Morishima Y, Miyamura K, Kojima S, Ueda R, Morishita Y, Sao H, Tanimoto M, Ohno R, Sobue R, Hirano M.
    Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
    [Abstract] [Full Text] [Related]

  • 19. Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation.
    Tam YK, Klingemann HG.
    Biol Blood Marrow Transplant; 1999 Apr; 5(4):231-42. PubMed ID: 10465103
    [Abstract] [Full Text] [Related]

  • 20. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR, Parreira A, Ascensão JL.
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.